Predictive Oncology Inc. Announces Newest Board Member
April 27 2021 - 8:30AM
Predictive Oncology (NASDAQ: POAI), a
knowledge-driven company focused on applying artificial
intelligence (“AI”) to personalized medicine and drug discovery, is
excited to announce today their newest Board Member Dr. Christina
Jenkins.
Dr. Christina Jenkins is a strategic advisor and venture
investor whose expertise spans clinical medicine, venture capital,
health systems and health plans. She applies her unique perspective
of providers, payers, and consumers to help leaders optimize growth
and health outcomes.
Dr. Jenkins is a Venture Partner at Phoenix Venture Partners
(PVP), where she co-leads the firm’s seed-stage investment strategy
in the healthcare/life sciences vertical. She is focused on
hardware-enabled platform companies that are transforming the way
we diagnose, monitor, and treat health conditions. She also leads
investments for Portfolia’s FemTech and Active Aging and Longevity
funds, focusing on evidence-backed digital health and device
companies targeting the health of women.
Previously, Dr. Jenkins was the founding CEO of OneCity Health
Services, a subsidiary of NYC Health + Hospitals (H+H), where she
built a team to 130 people and led a successful $1.2B effort to
design and implement technology-enabled care models and accelerate
value-based payment (financial risk) readiness for 1M lives.
She is a Board Director for Independence Health Group (parent of
Independence Blue Cross and AmeriHealth Caritas), a Board Observer
for Madorra, and an advisory board member of multiple
value-generating healthcare companies.
"We are very fortunate to have Dr. Jenkins join our Board of
Directors. As a medical doctor she brings additional insight and
perspectives to our team. She has participated and led companies to
success in health services and will have an immediate impact at
Predictive Oncology and will strengthen our strategic positioning
in the market," said Chief Executive Officer J. Melville
Engle.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates
through three segments (Skyline, Helomics and Soluble Biotech),
which contain four subsidiaries: Helomics, TumorGenesis, Skyline
Medical and Soluble Biotech.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
TumorGenesis Inc. specializes in media that help cancer cells grow
and retain their DNA/RNA and proteomic signatures, providing
researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including
humans. Skyline Medical markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement, and
disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and
international divisions. Soluble Biotech is a provider of soluble
and stable formulations for proteins including vaccines,
antibodies, large and small proteins, and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release contain
forward-looking statements. These forward-looking statements
reflect our current expectations and projections about future
events and are subject to substantial risks, uncertainties and
assumptions about our operations and the investments we make. All
statements, other than statements of historical facts, included in
this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Our actual future
performance may materially differ from that contemplated by the
forward-looking statements as a result of a variety of factors
including, among other things, factors discussed under the heading
“Risk Factors” in our filings with the SEC. Except as expressly
required by law, the Company disclaims any intent or obligation to
update these forward-looking statements.
Investor Relations Contact:
Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024